WHWK SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWWhitehawk Therapeutics Reports Q3 2026 Financial Results and Highlights Pipeline Progress

Nov 9, 2026

8-K

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

Sep 10, 2026

8-K

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Operational Progress

Aug 6, 2026

8-K

Whitehawk Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 12, 2026

8-K

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for CPT113 Linker-Payload

May 21, 2026

8-K

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

May 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

April 2025 ATM | Offering amount: $75,000,000

Apr 25, 2025

424B5

ATM | Offering amount: $13,500,000 | Amount sold to date: $0 | Float: 16,637,988

May 3, 2024

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 5,800,019 | Share price: $12.50 | Warrants amount: 2,426,493

Nov 4, 2022

424B5

ATM | Offering amount: $75,000,000

Mar 18, 2022

424B5

ATM | Offering amount: $75,000,000

Mar 17, 2022

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 17,629,522

Oct 1, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION

May 29, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 12, 2026

S-3

SHARE RESALE REGISTRATION | Shares amount: 41,668,500 | Warrants amount: 20,076,500

Mar 31, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 28, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Mar 18, 2025

S-8

Registration

Feb 12, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Feb 19, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Feb 18, 2025

Ownerships

TYPE

HEADLINE

FILED AT

4/A

Giacobello Scott M. (Reporting)

Sep 18, 2026

4/A

BALL BRYAN (Reporting)

Sep 18, 2026

4/A

Dornan David (Reporting)

Sep 18, 2026

4/A

Lennon David James (Reporting)

Sep 18, 2026

4/A

Dugan Margaret (Reporting)

Sep 18, 2026

Lennon David James (Reporting)

Sep 15, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 10, 2026

CORRESP

Form CORRESP - Correspondence

Jun 5, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jun 5, 2026

LETTER

Form UPLOAD - SEC-generated letter

May 22, 2025

CORRESP

Form CORRESP - Correspondence

May 13, 2025

LETTER

Form UPLOAD - SEC-generated letter

May 7, 2025

Whitehawk Therapeutics Inc WHWK · SEC Filings